What is Inimmune?
Inimmune operates as a specialized clinical-stage biotechnology enterprise, focusing on the discovery and development of advanced immunotherapies. The company's core competency lies in the engineering of Toll-like receptor (TLR) agonists, which serve as critical components in modern vaccine adjuvants and therapeutic interventions for cancer, allergies, and autoimmune disorders. By leveraging a robust pipeline of both clinical and pre-clinical assets, Inimmune maintains a competitive edge in the immunology sector. Their strategic approach involves deep collaboration with academic institutions and industry partners, ensuring that their novel therapeutic solutions are grounded in rigorous scientific inquiry and translational research excellence.
How much funding has Inimmune raised?
Inimmune has raised a total of $22M across 1 funding round:
Series A
$22M
Series A (2020): $22M with participation from Two Bears Capital
Key Investors in Inimmune
Two Bears Capital
A venture capital firm specializing in early-stage and growth-stage investments within the biotechnology and life sciences sectors.
What's next for Inimmune?
Following this major strategic investment, Inimmune is expected to prioritize the advancement of its lead TLR agonist candidates through critical clinical trial phases. The influx of capital will likely be deployed to scale internal R&D operations, expand the company's intellectual property portfolio, and potentially initiate new partnerships to broaden the reach of their vaccine adjuvant technology. As the firm transitions from early-stage development to more mature clinical milestones, the focus will remain on demonstrating efficacy and safety in human trials, thereby increasing the valuation of their therapeutic pipeline and positioning the company for future long-term growth in the global healthcare market.
See full Inimmune company page
